Brief: Novocure Announces Favorable Independent Data Monitoring Committee Recommendation To Continue Phase 3 PANOVA-3 Clinical Trial

NovoCure

21/07/2023 13:47

July 21 (Reuters) - Novocure Ltd  NVCR.O :
    * NOVOCURE ANNOUNCES FAVORABLE INDEPENDENT DATA MONITORING
COMMITTEE RECOMMENDATION TO CONTINUE PHASE 3 PANOVA-3 CLINICAL
TRIAL OF TUMOR TREATING FIELDS THERAPY IN PANCREATIC CANCER
    * NOVOCURE LTD - PRE-SPECIFIED INTERIM ANALYSIS CONCLUDED
THAT
FULLY ENROLLED PANOVA-3 CLINICAL TRIAL SHOULD PROCEED TO FINAL
ANALYSIS AS PLANNED
    * NOVOCURE LTD - INTERIM ANALYSIS RESULTED IN A DMC
RECOMMENDATION
THAT CLINICAL TRIAL PROCEED TO FINAL ANALYSIS
    * NOVOCURE LTD- LOOK FORWARD TO REVIEWING PANOVA-3 DATA IN
2024

Source text for Eikon:  ID:nBwcdJRsya 
Further company coverage:  NVCR.O 

 ((Reuters.Briefs@thomsonreuters.com;))